Infectious Disease · PANCE / PANRE

Cytomegalovirus (CMV)

Ubiquitous beta-herpesvirus — usually asymptomatic in healthy hosts but causes serious disease in neonates and immunocompromised patients.

Also known as: CMV, HHV-5, cytomegalovirus, congenital CMV

Overview

Human cytomegalovirus (HHV-5) is a double-stranded DNA beta-herpesvirus establishing lifelong latency in myeloid progenitors and other cells after primary infection. Manifestations depend critically on host immune status and timing (congenital vs. acquired).

Epidemiology

Seroprevalence rises with age; ~50% of US adults by 40, >90% in lower-income settings. Most common congenital viral infection (~1 in 200 live births; ~10% symptomatic at birth). Leading non-genetic cause of childhood sensorineural hearing loss.

Try two board-style Cytomegalovirus questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1Infectious DiseaseMedium
A 45-year-old man with HIV (CD4 count 45 cells/µL, not on antiretroviral therapy) develops painless, progressive visual changes, including floaters and a curtain-like loss of vision. Ophthalmologic examination shows hemorrhagic retinal lesions with perivascular exudates in a 'pizza pie' pattern. Which of the following is the most likely diagnosis?
  • ACryptococcal chorioretinitis
  • BAcute retinal necrosis
  • CToxoplasma retinochoroiditis
  • DCytomegalovirus retinitis
Reveal answer & full explanation
Correct answer: D — Cytomegalovirus retinitis
  • ACryptococcal chorioretinitis
  • BAcute retinal necrosis
  • CToxoplasma retinochoroiditis
  • DCytomegalovirus retinitis

Why Cytomegalovirus retinitis is correct

  • CMV retinitis is the most common ocular opportunistic infection in advanced AIDS and characteristically appears once the CD4 count falls below 50 cells/µL, as in this patient.
  • The painless, progressive floaters and a curtain of vision loss reflect full-thickness necrotizing retinitis.
  • The 'pizza pie' fundus — hemorrhage plus perivascular exudates and necrosis — is the classic sign.
  • Management is systemic valganciclovir (with intravitreal ganciclovir for sight-threatening lesions) plus prompt antiretroviral therapy.

Why the others are wrong

  • Cryptococcal chorioretinitis — Cryptococcus in AIDS causes meningitis and, rarely, papilledema, not hemorrhagic 'pizza pie' retinitis; picking it confuses the feared CNS opportunist with the ocular one (buzzword-matching on HIV).
  • Acute retinal necrosis — a VZV/HSV peripheral necrotizing retinitis that is typically painful with prominent anterior-chamber and vitreous inflammation and occurs in immunocompetent hosts; the painless course and CD4 <50 point away (premature closure on 'viral retinitis').
  • Toxoplasma retinochoroiditis — produces a focal yellow-white 'headlight in the fog' lesion next to an old chorioretinal scar with dense vitritis, not diffuse hemorrhagic perivascular exudates (confused-with-CMV trap).

Teaching point

  • In AIDS with CD4 <50, painless visual loss and a hemorrhagic 'pizza pie' retina is CMV retinitis until proven otherwise.
Question 2Infectious DiseaseMedium
A 3-day-old term newborn is evaluated after failing the universal newborn hearing screen in both ears. He was small for gestational age at birth. On examination he has microcephaly, hepatosplenomegaly, and scattered petechiae. Laboratory studies show conjugated hyperbilirubinemia, mild transaminitis, and thrombocytopenia. Head ultrasound reveals periventricular calcifications. Which of the following is the most appropriate next diagnostic test?
  • ACMV PCR on a neonatal urine or saliva sample
  • BToxoplasma IgM and IgG serology on infant serum
  • CQuantitative plasma CMV PCR at one month of age
  • DCMV IgM and IgG serology on infant serum sample
Reveal answer & full explanation
Correct answer: A — CMV PCR on a neonatal urine or saliva sample
  • ACMV PCR on a neonatal urine or saliva sample
  • BToxoplasma IgM and IgG serology on infant serum
  • CQuantitative plasma CMV PCR at one month of age
  • DCMV IgM and IgG serology on infant serum sample

Why CMV PCR on a neonatal urine or saliva sample is correct

  • This newborn has the classic congenital CMV phenotype: SGA, microcephaly, hepatosplenomegaly, petechiae, conjugated hyperbilirubinemia, thrombocytopenia, periventricular calcifications, and a failed hearing screen (CMV is the leading non-genetic cause of childhood sensorineural hearing loss).
  • The confirmatory test is CMV PCR on neonatal urine or saliva obtained within the first 21 days of life; sampling during this window distinguishes true congenital infection from perinatally acquired CMV.
  • Early diagnosis matters because symptomatic congenital CMV with CNS involvement or hearing loss is treated with oral valganciclovir for 6 months, which improves hearing and developmental outcomes.

Why the others are wrong

  • CMV IgM and IgG serology on infant serum sample: neonatal antibody testing is unreliable because IgG reflects transplacental maternal antibody and IgM is insensitive in the newborn, so it cannot confirm congenital infection.
  • Toxoplasma IgM and IgG serology on infant serum: congenital toxoplasmosis is on the TORCH differential but classically produces diffuse (not periventricular) intracranial calcifications and chorioretinitis, so pursuing it first delays the higher-yield CMV PCR.
  • Quantitative plasma CMV PCR at one month of age: a positive test after 21 days of life cannot distinguish congenital from perinatally acquired infection, defeating the purpose of testing in this window.
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Cytomegalovirus (CMV) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Daycare exposure, healthcare work (high seroconversion)
  • Sexual contact, blood transfusion (rare with leukoreduction), organ/HSC transplantation
  • Pregnancy with primary CMV infection (highest risk of congenital transmission)
  • Immunocompromise: HIV with CD4 <50, solid organ/HSC transplant, high-dose immunosuppression

Pathophysiology

Initial replication in mucosal epithelium followed by dissemination via infected monocytes. Establishes latency in CD34+ progenitor cells; reactivation occurs with immune compromise. Pathogenic effects include direct cytopathic injury (giant cells with 'owl's-eye' intranuclear inclusions), endothelial dysfunction, and immune-mediated damage.

Clinical presentation

Symptoms

  • Immunocompetent adults: heterophile-negative mononucleosis (prolonged fever, fatigue, mild hepatitis, lymphocytosis); pharyngitis and adenopathy less prominent than EBV
  • Congenital CMV: hearing loss (most common, often progressive and late-onset), microcephaly, intracranial calcifications (periventricular), chorioretinitis, hepatosplenomegaly, jaundice, petechiae ('blueberry muffin' rash), IUGR
  • Immunocompromised (especially HIV CD4 <50 or post-transplant): retinitis (floaters, painless vision loss), colitis (diarrhea, abdominal pain, GI bleeding), esophagitis (large solitary ulcers), pneumonitis (post-HSCT), encephalitis/polyradiculitis

Signs / physical exam

  • Hepatosplenomegaly; transaminitis
  • CMV retinitis: 'pizza pie' or 'cottage cheese with ketchup' appearance — yellow-white retinal infiltrates with hemorrhage on funduscopy
  • Congenital: small for gestational age, microcephaly, blueberry muffin rash, sensorineural hearing loss

Classic findings

CMV retinitis in advanced HIV (CD4 <50): perivascular hemorrhages with fluffy yellow-white exudates. Congenital CMV: periventricular calcifications (vs. diffuse intracranial calcifications in toxoplasmosis).

Differential diagnosis

  • EBV mononucleosis — Pharyngitis and prominent lymphadenopathy; positive heterophile and VCA IgM
  • Acute HIV — Trunk rash, oral ulcers, recent high-risk exposure; HIV RNA
  • Toxoplasmosis — Cat exposure, lymphadenopathy without pharyngitis; toxo IgM/IgG
  • Viral hepatitis — Marked transaminitis, jaundice; hepatitis A/B/C serologies
  • Drug-induced hepatitis — Recent medication; resolves with discontinuation
  • Other congenital infections (TORCH) — Toxoplasmosis, rubella, syphilis, HSV, Zika — overlapping features; targeted testing

Diagnostic workup

Diagnostic criteria

Congenital CMV: positive PCR on neonatal urine/saliva within 21 days of birth. End-organ disease: tissue biopsy with characteristic cytomegalic inclusions (owl's eye) and positive immunohistochemistry or PCR.

Labs

  • Immunocompetent: CMV IgM (acute) and IgG with avidity (low avidity supports primary infection); CMV PCR (viremia)
  • Immunocompromised: quantitative plasma CMV PCR (viral load monitoring guides preemptive therapy in transplant)
  • Tissue PCR or immunohistochemistry from biopsy (gold standard for end-organ disease — retina, colon, esophagus, lung)
  • Congenital: CMV PCR on neonatal urine or saliva within first 21 days of life (after 21 days cannot distinguish congenital from perinatal acquisition)
  • CBC, CMP, LFTs

Imaging

  • Head ultrasound or MRI for suspected congenital CMV — look for periventricular calcifications, ventriculomegaly, white matter abnormalities, polymicrogyria
  • Dilated funduscopy for retinitis screening if HIV CD4 <50
  • Endoscopy with biopsy for suspected GI CMV

Diagnostic algorithm

HostCommon SyndromeDiagnostic TestFirst-line Therapy
Healthy adultHeterophile-negative monoCMV IgM, PCRSupportive
Newborn (congenital)Hearing loss, calcificationsUrine/saliva PCR <21 daysValganciclovir x 6 mo if symptomatic
HIV CD4 <50Retinitis, colitis, esophagitisFunduscopy, tissue PCRIV ganciclovir → val maintenance
Post-transplantViremia, tissue-invasive diseaseQuantitative plasma PCRVal/ganciclovir; letermovir prophylaxis
CMV disease manifestations and management by host immune status.

Treatment

First-line

  • Immunocompetent: supportive care — antivirals not indicated
  • End-organ CMV disease (transplant, HIV): IV ganciclovir 5 mg/kg q12h induction × 14-21 days, then valganciclovir 900 mg PO daily maintenance
  • Valganciclovir 900 mg PO BID — oral option for many CMV syndromes including induction of mild-moderate retinitis
  • Congenital symptomatic CMV with CNS involvement or sensorineural hearing loss: valganciclovir 16 mg/kg PO BID × 6 months (improves hearing/developmental outcomes — Kimberlin NEJM 2015)

Second-line / adjunct

  • Foscarnet — ganciclovir resistance or marrow toxicity; nephrotoxic, electrolyte abnormalities
  • Cidofovir — third-line; significant nephrotoxicity
  • Letermovir — prophylaxis post-HSCT (terminase inhibitor; no marrow toxicity)
  • Maribavir — refractory/resistant CMV post-transplant (UL97 inhibitor)

Complications

  • Congenital: sensorineural hearing loss (progressive in 50%), developmental delay, seizures, cerebral palsy, vision loss
  • Post-transplant CMV: tissue-invasive disease, indirect effects (acute and chronic allograft rejection, opportunistic infections, post-transplant lymphoproliferative disorder)
  • HIV: blindness from retinitis, severe colitis, encephalitis
  • Guillain-Barre, hemolytic anemia, immune thrombocytopenia (rare in immunocompetent)

PANCE pearls

  • Heterophile-negative mononucleosis in an adult — order CMV serology and HIV testing.
  • Universal newborn CMV screening is gaining traction; in many states targeted testing of newborns who fail hearing screen.
  • Pregnancy: behavioral hygiene (handwashing after diapers, no sharing of utensils/cups with young children) reduces maternal seroconversion; hyperimmune globulin and antivirals studied but not standard.
  • Solid organ transplant donor+/recipient- (D+/R-) is the highest CMV risk combination — extended valganciclovir prophylaxis recommended.
  • Letermovir has displaced ganciclovir for CMV prophylaxis after allogeneic HSCT due to safety profile.

References

  • Kimberlin 2015 — Valganciclovir for symptomatic congenital cytomegalovirus disease (NEJM)
  • AST IDCOP 2019 — Cytomegalovirus in solid organ transplant recipients — Guidelines of the American Society of Transplantation
  • DHHS OI Guidelines — Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults with HIV — CMV section

Practice Infectious Disease questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.